Notice of AGM

RTW Biotech Opportunities Ltd

18 April 2024

 

LEI: 549300Q7EXQQH6KF7Z84

18 April 2024

RTW Biotech Opportunities Ltd
(the "Company")

Notice of Annual General Meeting

RTW Biotech Opportunities Ltd announces that its Annual General Meeting ("AGM") will be held at 1^st Floor Royal Chambers, St Julian's Avenue St Peter Port, Guernsey on 16 May 2024 at 2pm BST. The Notice of AGM was dispatched to all shareholders on 17 April 2024.

A copy of the Notice of AGM has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism The Notice of AGM may also be viewed on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd

The Annual Report and Audited Financial Statements for the year ended 31 December 2023 (the "Annual Report") is also available on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd

You will not have received a hard copy proxy form for the AGM in the post. You can instead submit your proxy vote electronically by accessing the shareholder portal at www.signalshares.com, logging in and selecting the 'Vote Online Now' link. Full details of how to vote are set out in the Notes to the Notice of Meeting. Please submit your proxy vote so as to reach the Company's registrar as soon as possible and in any event no later than 2pm BST on 14 May 2024 or, if you are a CREST member, by using the service provided by Euroclear. Shares held on your behalf by a broker or nominee must be voted by the broker, per your instructions, and cannot be voted at www.signalshares.com. The completion of the form of proxy will not preclude a member from attending and voting in person at the meeting if it is so allowed.

If any shareholder has questions related to the business of the AGM, please submit your queries to [e-mail] by 2pm BST on 14 May 2024. We will endeavour to answer every shareholder question and responses will be posted on the Company's website after the AGM.

For Further Information

RTW Investments, LP	[phone]
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations	[e-mail]
Buchanan (PR & Communications Adviser)	[phone]
Charles Ryland
Henry Wilson
George Beale
Deutsche Numis (Joint Corporate Broker)	[phone]
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities (Joint Corporate Broker)	[phone]
Edward Peel
Alex Penney
Cadarn Capital (Distribution & IR Partner)	[phone]
David Harris
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director	[phone]
Morgan Stanley Fund Services USA LLC	[phone]

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

 

END